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Introduction
　Gefitinib is a molecularly targeted drug for oral administration, 
a selective epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitor. It is effective for patients with lung cancer 
who have EGFR mutation and enables long-term survival of 
patients with advanced disease (1-3). When patients survive 
for a long period of time, their complications becomes an 
important problem, not only control of their cancer. Here, 
we report a rare complication of infectious cerebral 
thromboembolism caused by endocarditis in a patient with 
lung cancer during long-term administration of gefitinib.
Case Presentation
　An 84-year-old Asian female with no smoking history 
was admitted with a 2-month history of cough, appetite loss, 
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Case presentation
　An 84-year-old Asian female with lung cancer (adenocarcinoma, cT4N3M1b stage IV PUL BRA OSS ADR) was treated by 
gefitinib for two years. The primary tumor was markedly reduced, and bone metastasis had almost disappeared. However, the 
patient became unconsciousness with general edema and died two days after falling unconsciousness. In the autopsy, it was 
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general malaise, lumbago, keeping her bedbound. Chest 
X-ray and computed tomographic imaging of the chest 
demonstrated a bulky tumor in the upper lobe of the left lung 
(Figures 1A and 2A) and small nodules as pulmonary 
metastases. Bone scintigram revealed multiple bone metastases 
(Figure 3A). A diagnosis of lung cancer (adenocarcinoma, 
cT4N3M1b stage IV PUL BRA OSS ADR) was made based 
on the findings of a trans-bronchial lung biopsy. Chemotherapy 
with gefitinib was started as therapy. After three weeks, she 
could walk and left the hospital. The therapeutic response 
was partial response (PR) with no severe adverse effects. 
After leaving hospital, gefitinib therapy was continued, her 
activities of daily living improved, she could resume her 
previous life, and returned for a follow-up visit still able to 
walk. One year and 3 months after onset, she was admitted 
emergently to hospital because of acute pyelonephritis. As a 
result of repeated urinary tract infection, she became 
bedbound because of pyogenic spondylitis as a result of 
methicillin-resistant Staphylococcus aureus (MRSA) and was 
moved to the Department of Orthopedics in our hospital. 
One year and 11 months after onset, she was moved to the 
Department of Internal Medicine again for the purpose of 
lung cancer follow-up. The primary tumor was markedly 
reduced on chest X-ray (Figure 1B) and computed tomography 
(Figure 2B), and bone metastasis had almost disappeared 
(Figure 3B). Tumor markers were in the normal range. 
Course of CEA was presented in Figure 4. After three weeks 
of hospitalization, diarrhea, vomiting, cough, sputum, hematuria 
and fever were observed and CRP was increased on a 
blood test. After four weeks of hospitalization, she became 
unconsciousness with general edema. It was highly suspicious 
of cerebral accident including brain metastasis and investigated 
about brain but not done about cardio-vascular and lung. 
Brain MRI revealed multiple cerebral thromboses (Figure 
5), and the patient died two days after falling unconsciousness, 
two years after onset. 
　In the autopsy, 600 ml fresh blood was observed in the 
pericardium, and was considered cardiac tamponade. 
Verruciform adhered to the heart inside the left ventricle 
outflow at the aortic valve (Figure 6A), and was diagnosed 
as infectious endocarditis (Figure 6B). On the surface above 
the bleeding in the epicardium and right atrium from the 
Figure 1.  Chest X-ray at onset (A, left) and one year and 11 months after onset 
(B, right). 
Figure 2.  Computed tomography at onset (A, left) and one year and 11 months
 after onset (B, right). 　　　　　　　　　　　　　　　　　　　　　　　
Figure 3.  Bone scintigram at onset (A, left) and 
one year and 11 months after onset (B, right). 
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aortic valve side, a verruca was observed on an aortic valve, 
and an image considered to show a rupture was seen in the 
right atrium wall, which is equivalent to the back of the 
verruca. On Gram staining, many Gram-positive cocci were 
observed in infectious vegetation and the cardiac muscle 
wall (Figure 6C). An inflammatory cell-invasive lesion that 
contained neutrophils in blood vessels was observed in the 
cerebrum and fibrin was deposited in the blood vessels, 
which was diagnosed as infectious cerebral thromboembolism 
(Figure 7). Thus, repeated urinary tract infection had resulted 
in pyogenic spondylitis, bacteremia, and infectious endocarditis, 
and finally brought on infectious cerebral thromboembolism 
and cardiac tamponade, resulting in death. The cause of death 
was cardiac tamponade. The sudden loss of consciousness 
was caused by multiple infectious cerebral thromboembolisms. 
Although lung cancer progression was not found by a 
pathological approach, marked adenocarcinoma remained as 
part of the primary lesion in the left upper lobe and did not 
show metastasis to other areas. General edema was caused 
by heart failure. Although a small infarcted lesion of cerebral 
denaturation by infectious thrombotic embolism, which 
occurs frequently, was observed, a large infarcted lesion was 
not recognized.
Discussion
　Gefitinib is clearly effective for patients with lung cancer 
who have EGFR mutation compare with cytotoxic 
chemotherapy in progression-free survival and response rate 
(1-3). To evaluate the impact of gefitinib against overall 
survival, Japanese patients with EGFR mutations who began 
Figure 5.  Diffusion-weighted image of brain MRI at 
falling unconsciousness. Multiple peripheral high in-
tensity areas were observed in left cerebral hemispheric 
dominant but also right occipital lobe and both cerebel-
lum.
first-line systemic therapy was investigated before and after 
gefitinib approval in Japan (4). It was significantly longer 
among the EGFR-mutant patients treated after gefitinib 
approval and median survival time prolonged to 27.2 months 
compared with the before gefitinib approval of 13.6 months. 
While some cancer patients show marked prolongation of 
life, complete recovery is rare. The present case showed an 
effect of gefitinib therapy on the tumor, and improved from 
PS 3 to 1. As urinary tract infection developed, PS worsened 
again, and death from cardiac tamponade and infectious 
cerebral thromboembolism occurred as a result of infectious 
endocarditis. The responsible bacteria were considered to be 
MRSA, because many Gram-positive cocci were observed 
in part of the verrucous vegetation, which was the same as in 
pyogenic spondylitis. Infectious endocarditis is a disease 
characterized by bacterial inflammation in the endocardium. 
Disordered cardiac blood flow makes fissures in the 
endocardium, which usually has a smooth surface, and 
bacteria in the blood stream attach to it. Bacterial proliferation 
forms verrucous vegetation. Once vegetation develops at a 
cardiac valve, it destroys the valve and the surrounding 
tissue, and causes regurgitation and heart failure. If some of 
the vegetation separates and enters the blood stream, it will 
move to the brain etc. and cause an embolism. Although it is 
not a frequent infection, 10 to 50 persons/million/year, 
infectious endocarditis has a high fatality rate of 16-25% 
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Figure 7. HE stain of the cerebrum in autopsy. Low power field (A, left) and high power field (B, right). 
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Figure 6. Macroscopic image of interior surface of heart (A), HE stain of heart insection (B), and Gram stain of 
verruca (C) in autopsy. Infectious verruca (arrow) adhered at aortic valve of left ventricular outflow tract. 
（B） （C）
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(5-6). In particular, it becomes critical when infectious 
endocarditis is complicated with cerebral embolism. In an 
observational cohort study of 1779 patients with infectious 
endocarditis, Staphylococcus aureus was the leading cause 
and included 25% of MRSA (7). We did not diagnose 
infectious endocarditis while the present patient was alive. 
Because the prognosis of patients with lung cancer has been 
extending, we should carefully auscultate and examine by 
ultrasound when an abnormal cardiac murmur is found. 
Moreover, early treatment of bacteremia is needed.
Conclusion
　We have reported a patient with lung cancer who developed 
cerebral thromboembolism from infectious endocarditis 
during gefitinib therapy. While long-term survival can be 
expected in patients with stage IV lung cancer by molecular-
targeted agents, cautious management is warranted for 
complications, the same as for the primary disease. 
Abbreviations
　EGFR, epidermal growth factor receptor; MRSA, methicillin-
resistant Staphylococcus aureus; 
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